Keywords
CTC
CA125
CA153
Submitted : 2023-08-26
Accepted : 2023-09-10
Published : 2023-09-25
Abstract
Objective: To explore the detection and clinical significance of peripheral blood CTC, CA125, CA153, and CEA levels in patients with DCIS. Methods: 210 patients who received surgical treatment for breast cancer in our hospital from January 2019 to December 2022 were selected as the research subjects. According to the postoperative pathology, 100 cases were divided into breast cancer and 110 benign breast tumor groups. One hundred ten healthy patients undergoing physical examination during the same period were selected as the control group. CA153, CA125, and CEA levels were observed in the three groups. Results: The levels of CA153, CA125, and CEA in the breast cancer group were significantly higher than those in the benign breast tumor group and the control group (P < 0.05); the levels of CA153, CA125, and CEA in the benign breast tumor group were all higher than those in the control group, but the differences were not statistically significant; among the three tumor markers, CA153 has the highest sensitivity at 39.00%, CA125 has the second highest sensitivity at 18.00%, and CEA has the lowest sensitivity at 17.00%; The sensitivity of the two joint tests of CA153+CA125, CA153+CEA, and CA125+CEA for the diagnosis of breast cancer were 50.00%, 48.00%, and 26.00% respectively; the sensitivity of the three joint tests is the highest, reaching 53.00%, while the specificity of the joint tests was lower than the individual tests. Conclusion: Detection of peripheral blood CTC, CA125, CA153, and CEA levels has specific reference significance for the treatment and prognosis of DCIS patients.
References
Wang J, Lu X, Wu Zhou J, et al., 2021, Study on the Relationship Between Circulating Tumor Cells in Peripheral Blood and Clinicopathological Characteristics of Breast Cancer. Chinese Journal of Surgical Oncology, 13(3): 242–245.
Cai J, Gan J, Chen Q, et al., 2020, Analysis of the Role of Peripheral Blood Circulating Tumor Cell (CTC) Detection in Early Detection of Postoperative Metastasis of Breast Cancer. World Comprehensive Medicine, 6(5): 132–134.
Wang X. KRT19 and CEACAM5 mRNA Double-Labeled Circulating Tumor Cells (CTCs) Indicate Poor Prognosis in Breast Cancer Patients. 2019, Tianjin Medical University.
Zhang X, Chen D, Wang Q, et al., 2018, Explore the Expression of CD44~+/CD24~- Cells in the Peripheral Blood of Breast Cancer Patients at Different Stages. Chinese and Foreign Medical Research, 16(3): 83–84.
Zhao C, Dong L, Zhang J, et al., 2016, Clinical Significance of CD44~+/CD24~- Expression in Peripheral Blood Lymphocytes of Breast Cancer Patients. Chinese Community Physicians, 32(29): 141–142.
Cao L. Study on the Correlation Between Peripheral Blood-Related Test Indicators and Pathological Characteristics of Breast Cancer Patients. 2018, Binzhou Medical College.
Zhang L, Liu Y, Duan W, et al., 2018, Changes in Some Peripheral Blood Indicators in Breast Cancer Patients and the Diagnostic Value of Tumor Markers. Chinese Medicine, 13(3): 421–425.
Chen X, 2015, Correlation Between Distant Breast Cancer Metastasis and Peripheral Blood Lipid Levels. Journal of Practical Clinical Medicine, 19(23): 66–68.
Zheng P, 2015, Application of Peripheral Blood CEA, CA153, CA125 in Clinical Breast Cancer Screening. Chinese Maternal and Child Health Care, 30(16): 2520–2522.
Luo Y. The Role of Monitoring VEGF, CA15-3, CA125, and TPS in Breast Cancer Patients’ Peripheral Blood in Evaluating Neoadjuvant Chemotherapy’s Efficacy. 2013, Zunyi Medical College.
Hua B, Ahtibek T, Lu X, et al., 2012, Discussion on the Significance of Serum Tumor Marker ?_2 Microglobulin, Carcinoembryonic Antigen, CA153, and CA125 Detection in Breast Cancer Clinical Practice. Chinese Breast Cancer Journal of Diseases, 6(3): 253–258.
Jiang X, Yi Y, Xu K, et al., 2009, Discussion on the Clinical Value of Joint Detection of Peripheral Blood Telomerase Activity and Tissue Peptide-Specific Antigen for Breast Cancer. Chinese Journal of Modern Medicine, 19(20): 3162–3164 + 3167.
Liu L, Chen L, Lin Y, et al., 2009, Application of Joint Detection of Serum CA153, CA125, and CEA in the Diagnosis of Breast Cancer. International Journal of Laboratory Medicine, 30(9): 858–859.
Xu M, Sheng B, Cui H, 2022, Changes in Some Peripheral Blood Indicators in Breast Cancer Patients and the Diagnostic Value of Serum CA125, CA153, and CEA Detection. Chinese and Foreign Medical Research, 20(21): 66–70.
Li Y. The Relationship Between NLR, PLR, LMR, SII, and D-dimer in Peripheral Blood Before Surgery and Clinicopathological Characteristics and Prognosis in Patients with Ovarian Epithelial Cancer. 2021, Hebei Medical University.
Sun X. Analysis of the Diagnostic Value Of Preoperative Peripheral Blood NLR, Fib Combined with CA125 for Epithelial Ovarian Cancer. 2020, Hebei Northern University.